Frequently asked questions
The montelukast API market suffered less from the COVID-19 pandemic, which resulted in a moderate decline of over 1.2% in revenue generated in 2020.
North America accounted for the highest share in the global montelukast API market regarding value and volume.
The rising prevalence of asthma is expected to drive market growth over the forecast period. The rise in respiratory diseases and the growing geriatric population are key factors driving the market growth.
Tablet had a major share in 2021, with more than 58% of the market revenue share. Besides, the chewable tablet is projected to witness the fastest growth.
Asthma had a major share in the global market in 2021 and is projected to continue its dominance over the forecast period.